{'fraction_non_alphanumeric': 0.0364656381486676, 'fraction_numerical': 0.025245441795231416, 'mean_word_length': 5.672897196261682, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of mutations in the novel FTD‐ALS gene, CYLD, on SFPQ protein

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders that share similar clinical and pathological hallmarks, as well as overlapping genetic aetiologies. Previously, we identified that mutations in CYLD can cause FTD‐ALS. CYLD is a lysine‐63 deubiquitinase, and the FTD‐ALS causal mutation CYLDM719V shows significantly increased deubiquitinase activity [Dobson‐Stone et al. 2020, Brain 143:783‐799]. CYLD is known to interact with the protein products of at least three established FTD and ALS genes. We sought to determine whether other FTD‐ALS proteins were influenced by modulation of CYLD.